Posters

Early experience with new TECNIS Eyhance monofocal intraocular lens in eyes with co-existing pathologies

Poster Details

First Author: M.Nanavaty UK

Co Author(s):    C. Holmes   S. Borkum                 

Abstract Details

Purpose:

To evaluate early experience with new Tecnis Eyhance monofocal intraocular lens (IOL) in eyes with co-existing pathologies.

Setting:

Sussex Eye Hospital, Brighton & Sussex University Hospitals NHS Trust, Brighton, United Kingdom.

Methods:

This was an observational study of first 10 consecutive patients undergoing new Eyhance IOL. The only exclusion criterion was an expected postoperative distance visual potential of less than 20/40. At one-month, assessments included: LogMAR uncorrected (UCDVA) and best-correct distance visual acuity (BCDVA), distance-corrected intermediate visual acuity (DCIVA) at 60cms, manifest refraction, defocus curve (-3.0D to +1.5D), Likert scale questionnaire for glare & halos (1=all the time; 2=only in certain lighting conditions; 3=occasionally not depending on lighting condition; 4=none at all) and visual satisfaction (1=not satisfied at all; 2=somewhat satisfied; 3=satisfied; 4=very satisfied). Only first eye of each patient was included.

Results:

Co-existing pathologies were: corneal astigmatism needing incision correction (n=1), previous macula-on retinal detachment (n=2), previous trauma with irregular pupil (n=1) and mild corneal guttate (n=1). Mean LogMAR (Snellen equivalent) UCDVA, BCDVA and DCIVA were 0.22+/-0.13 (20/30), 0.07+/-0.13 (20/20) and 0.49+/-0.11 (20/60) respectively. Mean spherical equivalent was -0.04+/-0.21 diopters. Defocus curve visual acuities were 0.84+/-0.11(20/130), 0.76+/-0.08 (20/110), 0.64+/-0.12 (20/90), 0.45+/-0.09 (20/50), 0.32+/-0.14 (20/40), 0.14+/-0.12 (20/25), 0.07+/-0.09 (20/20), 0.0+/-0.15 (20/30), 0.32+/-0.11 (20/40) and 0.55+/-0.14 (20/70) after -3.0, -2.5, -2, -1.5, -1, -0.5, 0, +0.5, +1.0, +1.5Diopters add respectively. Likert Scale for glare, halos and visual satisfaction were 2.44+/-1.01, 3.99+/-0.33 & 3.99+/-0.33 respectively.

Conclusions:

The new Tecnis Eyhance IOL performs better for intermediate vision even in eyes with co-existing pathologies with good overall patient satisfaction.

Financial Disclosure:

... research is funded, fully or partially, by a competing company, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented